News | February 03, 2022
Caplin Point Q3FY22 PAT at Rs 74.95 cr.
Caplin Point Laboratories has reported consolidated financial results for the period ended December 31, 2021.
Caplin Point Laboratories has reported consolidated financial results for the period ended December 31, 2021.
Restasis has been approved for use in the U.S. for nearly 20 years, but until today, there was no approved generic product of this drug
The acquisition will allow Dr. Reddy's to build on Nimbus Health's strengths and introduce medical cannabis-based medicines as a promising treatment option for patients
It has a total of 50 ANDA approvals from USFDA
Mental health issues are a cause for concern and in a conservative society like India. Thomas C Thottathil spoke to Krishna Veer Singh, Co-Founder and CEO of Lissun, a young start-up working in the space of mental health
The vaccine will be priced at Rs. 265 per dose and the applicator being offered at Rs. 93 per dose excluding GST
The tablets are indicated for the treatment of overactive bladder (OAB) in adults with symptoms of urge urinary incontinence, urgency, and frequency
The pharma division’s domestic business generated turnover of Rs. 219.85 crore for the last financial year
It will enable the company to branch out to new geographies and strengthen its presence in South Africa
Pegfilgrastim is indicated to reduce the duration of neutropenia and the incidence of febrile neutropenia in patients receiving chemotherapy
Subscribe To Our Newsletter & Stay Updated
